Identification and evaluation in-vitro of conserved peptides with high affinity to MHC-I as potential protective epitopes for Newcastle disease virus vaccines.
Epitope
Fusion
Hemagglutinin-neuraminidase
Newcastle disease virus
Peptide-based vaccine
Polymerase
Journal
BMC veterinary research
ISSN: 1746-6148
Titre abrégé: BMC Vet Res
Pays: England
ID NLM: 101249759
Informations de publication
Date de publication:
07 Oct 2023
07 Oct 2023
Historique:
received:
15
03
2023
accepted:
12
09
2023
medline:
9
10
2023
pubmed:
8
10
2023
entrez:
7
10
2023
Statut:
epublish
Résumé
Newcastle disease (ND) is a major threat to the poultry industry, leading to significant economic losses. The current ND vaccines, usually based on active or attenuated strains, are only partially effective and can cause adverse effects post-vaccination. Therefore, the development of safer and more efficient vaccines is necessary. Epitopes represent the antigenic portion of the pathogen and their identification and use for immunization could lead to safer and more effective vaccines. However, the prediction of protective epitopes for a pathogen is a major challenge, especially taking into account the immune system of the target species. In this study, we utilized an artificial intelligence algorithm to predict ND virus (NDV) peptides that exhibit high affinity to the chicken MHC-I complex. We selected the peptides that are conserved across different NDV genotypes and absent in the chicken proteome. From the filtered peptides, we synthesized the five peptides with the highest affinities for the L, HN, and F proteins of NDV. We evaluated these peptides in-vitro for their ability to elicit cell-mediated immunity, which was measured by the lymphocyte proliferation in spleen cells of chickens previously immunized with NDV. Our study identified five peptides with high affinity to MHC-I that have the potential to serve as protective epitopes and could be utilized for the development of multi-epitope NDV vaccines. This approach can provide a safer and more efficient method for NDV immunization.
Sections du résumé
BACKGROUND
BACKGROUND
Newcastle disease (ND) is a major threat to the poultry industry, leading to significant economic losses. The current ND vaccines, usually based on active or attenuated strains, are only partially effective and can cause adverse effects post-vaccination. Therefore, the development of safer and more efficient vaccines is necessary. Epitopes represent the antigenic portion of the pathogen and their identification and use for immunization could lead to safer and more effective vaccines. However, the prediction of protective epitopes for a pathogen is a major challenge, especially taking into account the immune system of the target species.
RESULTS
RESULTS
In this study, we utilized an artificial intelligence algorithm to predict ND virus (NDV) peptides that exhibit high affinity to the chicken MHC-I complex. We selected the peptides that are conserved across different NDV genotypes and absent in the chicken proteome. From the filtered peptides, we synthesized the five peptides with the highest affinities for the L, HN, and F proteins of NDV. We evaluated these peptides in-vitro for their ability to elicit cell-mediated immunity, which was measured by the lymphocyte proliferation in spleen cells of chickens previously immunized with NDV.
CONCLUSIONS
CONCLUSIONS
Our study identified five peptides with high affinity to MHC-I that have the potential to serve as protective epitopes and could be utilized for the development of multi-epitope NDV vaccines. This approach can provide a safer and more efficient method for NDV immunization.
Identifiants
pubmed: 37805566
doi: 10.1186/s12917-023-03726-w
pii: 10.1186/s12917-023-03726-w
pmc: PMC10559636
doi:
Substances chimiques
Epitopes
0
Viral Vaccines
0
Antibodies, Viral
0
Peptides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
196Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
iScience. 2020 Nov 20;23(12):101828
pubmed: 33305184
Genome Med. 2015 Nov 20;7:119
pubmed: 26589500
Adv Bioinformatics. 2016;2016:5484972
pubmed: 27667997
Methods Mol Biol. 2016;1349:1-24
pubmed: 26458826
Arch Med Res. 2021 May;52(4):362-370
pubmed: 33546870
Vet Microbiol. 2017 Jul;206:126-136
pubmed: 28024856
Nat Protoc. 2015 Jul;10(7):1098-115
pubmed: 26110715
Methods Mol Biol. 2016;1404:89-101
pubmed: 27076292
J Biomed Inform. 2015 Feb;53:405-14
pubmed: 25464113
Int J Mol Sci. 2016 May 04;17(5):
pubmed: 27153063
Virus Res. 2019 Nov;273:197750
pubmed: 31509776
J Immunol Res. 2017;2017:2680160
pubmed: 29445754
Vaccine. 2016 Jan 12;34(3):380-6
pubmed: 26620841
Virol Sin. 2011 Feb;26(1):1-7
pubmed: 21331885
Inform Med Unlocked. 2021;26:100768
pubmed: 34722851
Dev Comp Immunol. 2008;32(11):1398-404
pubmed: 18579202
Methods Mol Biol. 2016;1403:57-84
pubmed: 27076125
Adv Bioinformatics. 2019 Mar 18;2019:1270485
pubmed: 31011331
Vaccine. 2020 Oct 21;38(45):6990-7001
pubmed: 32951939
Front Vet Sci. 2021 Jun 15;8:610375
pubmed: 34212016
Cancer Immunol Immunother. 2014 Nov;63(11):1199-211
pubmed: 25134947
Methods Mol Biol. 2016;1404:51-57
pubmed: 27076289
Curr Top Med Chem. 2018;18(26):2202-2208
pubmed: 30417788
Infect Genet Evol. 2010 Jan;10(1):26-35
pubmed: 19800028
Nucleic Acids Res. 2019 Jan 8;47(D1):D339-D343
pubmed: 30357391
Avian Dis. 2017 Mar;61(1):16-24
pubmed: 28301239
Front Pharmacol. 2020 Dec 03;11:578382
pubmed: 33343349
Vet Res Forum. 2021 Spring;12(2):157-165
pubmed: 34345381
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
J Virol. 1994 Jul;68(7):4506-13
pubmed: 8207825